HOME >> MEDICINE >> NEWS
Fine-tuning naltrexone treatment for alcoholics

  • In 1994, the Food and Drug Administration approved naltrexone for the treatment of alcoholism.
  • It has since proven to be highly effective for many in recovery, but it does not work for everyone.
  • A recent study has found that individual metabolism may be a factor in naltrexone's effectiveness.
  • Its effectiveness can, in turn, be partially determined by measuring blood levels for naltrexone and its major metabolite, 6-beta-naltrexol.

The 1994 approval of naltrexone by the federal Food and Drug Administration was a milestone in the treatment of alcoholism. Naltrexone is a medication that decreases the rewarding effects of drinking and reduces the craving for alcohol that often leads people to relapse. Yet despite its effectiveness for many recovering alcoholics, it does not work for everyone. A study in the September issue of Alcoholism: Clinical & Experimental Research has found that, first, naltrexone's effectiveness may be influenced by individual metabolism, and second, this may be detected by measuring blood levels for the medication's major metabolite, 6-beta-naltrexol.

"Determining blood levels may be useful for patients who are not helped by the standard naltrexone dose," explained Mary E. McCaul, associate professor at Johns Hopkins University School of Medicine and lead author of the study. "This study demonstrates the importance of adjusting naltrexone dosage to ensure than an adequate blood level of 6-beta-naltrexol is achieved. If an individual does not achieve a therapeutic effect at the standard naltrexone dose of 50 milligrams per day, he or she may want to discuss a dose increase with the prescribing physician."

McCaul explained that drugs can have agonist and/or antagonist properties. Agonists activate a receptor to achieve their effect. Antagonists block the receptor from being activated by another endogenous (produced within the organism) or exogenous (produced outside the organism) chemical, bu
'"/>

Contact: Mary E. McCaul, Ph.D.
betsymc@jhmi.edu
410-955-5439
Alcoholism: Clinical & Experimental Research
13-Sep-2000


Page: 1 2 3 4

Related medicine news :

1. Using naltrexone to treat alcoholics with a Mediterranean drinking pattern
2. Rewards coupled with naltrexone effective in treating heroin and other opioid addictions
3. Hormonal treatment improves survival in high-risk prostate cancer patients
4. Chronic pain treatments more effective when taken together, new study shows
5. Brain activity prior to treatment flags vulnerability to antidepressant side effects
6. Cultural and social factors influence prostate cancer treatment
7. Research offers hope of new treatments for liver damage
8. First mouse model for multiple system atrophy points to new treatment targets for brain diseases
9. Stanford patient is first to test new treatment for peripheral arterial disease
10. Scientist works on innovative treatments for brain tumors
11. Blacks less likely to get expensive, newer heart treatments

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... NEW YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: ... data solutions, today announced that its MyDario product is expected to appear ... listings for when The Dr. Oz Show airs in your area: ... The nine-time Emmy award-winning, The ... ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/18/2017)... , Pa. and KALAMAZOO, Mich. , Sept. ... Penn. , and OptiMed Specialty Pharmacy of ... partnership to offer a strategic hub service that expedites ... highly sought-after personal spirometer, Spiro PD 2.0, and wellness ... A spirometer is a medical device used to measure ...
Breaking Medicine Technology:
Cached News: